Ingenia Therapeutics is focused on developing advanced therapeutics aimed at treating vascular diseases, particularly those affecting small blood vessels. The company has pioneered a unique technology that modifies endothelial and immune signaling pathways to effectively halt, reverse, and restore disorders related to blood vessels. This innovative approach targets a clinically validated signaling pathway essential for blood vessel development and stability, which plays a critical role in regulating vascular permeability, inflammation, and pathological angiogenesis. By addressing the underlying issues of inflamed and leaky blood vessels, Ingenia aims to provide transformative therapies for a range of conditions, including diabetic complications, retinal diseases, cancer, and various inflammatory disorders.

The company's pipeline includes a diverse array of therapeutic candidates, with a strategic focus on ophthalmic diseases as an initial indication. Ingenia has established partnerships with global biotech firms to enhance its research and development efforts. Their lead candidates are designed to activate the Tie2 receptor, a key regulator of vascular stability, independent of other ligands, which may lead to more effective and durable treatments. By restoring the structural and functional integrity of blood vessels, Ingenia Therapeutics aims to improve patient outcomes across multiple disease areas, including eye diseases, kidney diseases, and systemic inflammatory conditions.

United States

INGENIA Therapeutics is a biotechnology company specializing in the development of durable best-in-class therapeutic antibodies for capillary diseases. The company is focused on microvasculature healing and is located in Watertown, MA. INGENIA Therapeutics has raised a total funding of $7.01M over 1 round.

Ingenia Therapeutics

Company Details